Rodin Therapeutics   Report issue

For profit Phase 1
Founded: Cambridge MA United States (2013)
Status: Acquired by Alkermes (2019)

Organization Overview

First Clinical Trial
2018
NCT03577262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Rodin Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (2)

rdn-929 (2 trials)

ucb-j (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2